Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today recent submissions of two Investigational New Drug (IND) ...
Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injectorSarclisa administered via ...
Subcutaneous amivantamab offers a convenient alternative to IV administration for EGFR-mutated NSCLC, reducing infusion-related reactions and administration time. The PALOMA-3 trial confirmed ...
Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful Reduction ...
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...
A subcutaneous injection for thyroid eye disease posted an 81% proptosis response rate in an oral presentation Monday at ENDO 2026 in Chicago — numbers that, if they survive Phase III scrutiny, could ...
Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results